SermorelinExplore study findings
What the FDA's Geref records say about its former indications
2 numbered sourcesSource years 1996, 2013
Short chains of amino acids connected by peptide bonds are called peptides. Some can act on a pituitary receptor and prompt a hormone release. Sermorelin is a synthetic 29-residue fragment of human growth hormone–releasing hormone, with an amidated end. The history of Geref, a U.S. sermorelin acetate product, shows how a diagnostic approval and a treatment approval can address separate questions. [1, 2]
The FDA approved one Geref presentation in 1990 for evaluating whether the pituitary gland could release growth hormone (GH). That use measured a short response to a stimulus. The agency approved another presentation in 1997 for treating children with growth failure from idiopathic growth hormone deficiency. Idiopathic means that a definite cause has not been identified. The treatment indication concerned growth over time in children with a defined condition. [1]
The manufacturer notified the FDA in 2008 that the products were being discontinued and requested withdrawal of the approvals. The agency withdrew the approvals effective in 2009. In a 2013 Federal Register notice, the FDA determined that the specified products had been withdrawn from sale for reasons other than safety or effectiveness. The notice concerned those historical products and the reason they were withdrawn. It did not restore their approvals or evaluate a new formulation or indication. [1]
The older official record is the direct source for those regulatory events. A product's name, formulation, intended use and current regulatory status each matter when reading research or a label. An experiment examining hormone response or growth in a specific population supplies evidence about that experiment. It does not extend the historical approvals to unrelated uses. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 1.U.S. Food and Drug Administration. Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register (publication 2013-03-04). (opens in a new tab)
govinfo.gov↩ Back to text
- 2.Thorner M et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. Journal of Clinical Endocrinology & Metabolism (publication 1996-03). (opens in a new tab)
pubmed.ncbi.nlm.nih.gov↩ Back to text
